Drug Type Monoclonal antibody |
Synonyms AZD-5148 |
Target |
Action inhibitors |
Mechanism toxB inhibitors(Toxin B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Clostridium difficile infection | Phase 2 | United States | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Japan | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Australia | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Canada | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Denmark | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | France | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Germany | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Greece | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Hungary | 10 Dec 2025 | |
| Clostridium difficile infection | Phase 2 | Italy | 10 Dec 2025 |






